Nice clinical update review in the European Heart Journal, which is a journal of the European Society for Cardiology (ESC). However, that bolded sentence is the only mention of RVX-208 and BET inhibitors in the entire article. Nothing new here. First received for review June 28, 2017 and accepted in October 12, 2017. So most content was written H1 2017. Just to point out, one of the authors is Erik Stroes, who gave one of the ESC 2017 symposium talks on August 26, 2017. That presentation, along with those by Kausik Ray and Stephen Nicholls at that same symposium, are going to give you a much more BET-centric overview.

Promise of epigenetic modulation as a target in atherosclerotic patients

The Clinical Unmet need in the patient with Diabetes and ACS

Insights from the first trials in epigenetics in human: What is the way forward?

Summary | Insights from the first trials in epigenetics in human: What is the way forward?